Fig. 4: Overall survival probability. | Leukemia

Fig. 4: Overall survival probability.

From: Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

Fig. 4

There were three deaths in the trial. One patient died due to a cardiac arrest while in MMR. The cause of death was unknown for the second patient. A third patient died after falling from stairs. The latter two patients had regained deep molecular response at the level MR4 after re-commencing TKI therapy for MMR-loss. At 48 months, 53 patients were still under observation. CI confidence interval.

Back to article page